The research, spearheaded by Drs. Haluk Damgacioglu and Ashish Deshmukh, utilizes rigorous population-based data from the National Cancer Institute’s SEER (Surveillance, Epidemiology, and End Results) program. Over twenty years, the incidence of anal cancer was studied among a cohort exceeding 85,000 women who had previously been diagnosed with cervical cancer. What emerged from their comprehensive data analysis was a striking finding: women with a history of cervical cancer bear almost double the risk of developing anal cancer compared to their counterparts in the general population. This revelation challenges the current medical paradigm, which largely overlooks routine anal cancer screening for this vulnerable group.

At the molecular level, the shared etiological factor between cervical and anal cancers is the human papillomavirus (HPV), a pathogen well-known for its oncogenic potential. Both malignancies originate from HPV-infected epithelial tissues, yet clinical strategies have traditionally addressed these cancers independently. Dr. Deshmukh emphasizes that although the causative link through HPV has been understood for years, the natural history connecting cervical cancer survivorship to an elevated anal cancer risk over time has remained insufficiently elucidated. This gap in knowledge has, until now, left clinical guidelines static and ill-prepared to prevent subsequent malignancies in this demographic.

A critical challenge addressed by the study is the latency period characteristic of HPV-related carcinogenesis. HPV often integrates into the host genome and initiates neoplastic transformations that can take a decade or more to manifest as invasive cancer. This latent period complicates early detection, making the timing of surveillance efforts paramount. The researchers observed that anal cancer incidence not only remains elevated but actually increases with age in women with prior cervical cancer. Particularly, women aged between 65 and 74, who are more than 15 years post their initial cervical cancer diagnosis, showed the highest rates of anal cancer diagnoses. This finding underscores the insidious nature of HPV-mediated oncogenesis and accentuates the need for extended surveillance protocols well beyond the immediate survivorship phase.

Current recommendations for anal cancer screening prioritize populations at elevated risk due to factors such as HIV infection, immunosuppression post-organ transplantation, and a history of vulvar cancer. Surprisingly, women with previous cervical cancer—despite their demonstrated susceptibility—are not currently included in these guidelines. This omission stems partly from a historical paucity of robust epidemiological data and the logistical challenges surrounding anal cancer detection methods. Screening techniques encompass anal cytology, a procedure similar to cervical Pap smears, and high-resolution anoscopy for direct visualization of the anal canal, yet widespread availability and provider expertise remain limited.

The MUSC team’s findings shed light on a compelling public health question: given the demonstrated risk, should anal cancer screening be incorporated into post-cervical cancer follow-up care? Dr. Damgacioglu asserts that the data appreciably exceed accepted thresholds that typically mandate routine screening interventions. However, equitable implementation requires addressing the current systemic shortcomings in specialist availability and public awareness, factors that impede the translation of research findings into clinical practice. Additionally, prioritization strategies must be developed to allocate finite resources efficiently and screen those at highest risk.

The study’s methodology deserves particular scrutiny, given its reliance on SEER data—a gold standard in epidemiological cancer research. SEER’s comprehensive registries capture demographic, clinical, and survival information across diverse populations in the United States, enabling longitudinal analysis with minimal biases. By leveraging this robust database, the researchers could confidently stratify anal cancer incidence by age and latency since cervical cancer diagnosis, thereby producing nuanced risk estimates that inform screening timing. Such data-driven insight stands to influence guidelines profoundly, shifting recommendations from theoretical to evidence-based frameworks.

Further compounding the urgency of the study’s implications is the often asymptomatic progression of anal cancer during early stages. Without intentional screening, diagnosis frequently occurs at advanced stages, complicating treatment and diminishing prognosis. Incorporating anal cancer surveillance into survivorship care pathways could facilitate earlier detection, improve patient outcomes, and ultimately reduce morbidity and mortality related to HPV-driven malignancies. It also aligns with a broader movement toward personalized, risk-adapted oncology care.

Building on these pivotal findings, Dr. Deshmukh and collaborators have initiated a newly funded project harboring the objective of optimizing screening strategies for this high-risk population. In collaboration with prestigious institutions such as MD Anderson Cancer Center and the Icahn School of Medicine at Mount Sinai, the team aims to evaluate screening modalities, intervals, and implementation logistics. Such translational research embodies the continuum from epidemiological discovery to clinical application, promising to refine protocols that enhance patient care and resource stewardship in oncology.

Beyond the clinical domain, the study accentuates the broader importance of considering survivorship as a dynamic phase of oncological care. Long-term cancer survivors face unique challenges, including the risk of secondary malignancies that may arise due to shared etiological factors or consequences of initial treatment. Recognizing and addressing these risks through proactive surveillance is essential to improving quality of life and overall survival in this growing patient population.

In conclusion, new evidence illuminates the critical need to integrate anal cancer screening into post-cervical cancer care, particularly for older women many years after their initial diagnosis. The data reveal a persistent and escalating risk that current clinical guidelines have yet to address adequately. Advancing this discourse invites substantial changes in cancer survivorship care policies and clinical practice, underscoring the ever-evolving landscape of oncology driven by rigorous research and patient-centered innovation. By prioritizing high-risk groups and harnessing emerging screening technologies, the medical community can safeguard survivors from preventable cancers once deemed unrelated, transforming long-term survivorship into a reality of sustained health.

Subject of Research: People

Article Title: Anal cancer incidence among women with a history of cervical cancer by age and time since diagnosis

News Publication Date: 11-Sep-2025

Web References:
http://dx.doi.org/10.1001/jamanetworkopen.2025.31362

Image Credits: Medical University of South Carolina

Keywords: Cervical cancer, Cancer, Cancer risk, Cancer screening

Brain metastases, secondary tumors originating from cancers elsewhere in the body such as the lung, breast, skin, kidney, or digestive tract, pose intricate clinical dilemmas. The brain’s delicate architecture necessitates precision in radiation therapy, particularly with SRS, which delivers a concentrated dose in a one-time session. However, the efficacy and safety of SRS rely heavily on understanding the tumor’s lineage. Some cancers, like those rooted in lung tissue, exhibit high radiosensitivity and respond favorably to lower radiation doses, while others, including renal cancers, demonstrate resistance, demanding alternative dosing and treatment regimens. Accurately pinpointing the origin of brain metastases is therefore paramount to minimizing collateral damage and optimizing patient outcomes.

Historically, clinicians have grappled with the unstructured and often inconsistent format of medical records, especially when vital information is buried within extensive free-text clinical notes. Despite the existence of standardized coding systems such as the International Classification of Diseases (ICD), these codes frequently fall short in capturing the nuanced details necessary for specialized cancer treatments. ICD codes tend to be too broad, failing to distinguish between subtypes or the precise anatomical location of the primary tumor, which are essential variables in personalized treatment planning.

The MUSC research team circumvented this bottleneck by leveraging NLP, a sub-discipline of artificial intelligence focused on enabling machines to interpret human language. By training an algorithm to recognize semantic patterns, keywords, and contextual clues embedded in clinical notes, the model discerns specific cancer types and subtypes with unprecedented accuracy. For instance, terms like “ductal” signal breast cancer, whereas “melanoma” indicates skin cancer. This semantic precision allows for a more detailed and patient-specific cancer classification beyond the capabilities of conventional coding.

This NLP model was rigorously evaluated using a vast dataset comprising over 82,000 radiation oncology notes from the electronic health records (EHRs) of more than 1,400 patients treated with SRS for brain metastases. The performance of the NLP system was benchmarked against ground truth annotations manually verified by expert reviewers, confirming its ability to extract primary cancer diagnoses with over 90% accuracy overall. Remarkably, for prevalent cancers such as those of the lung, breast, and skin, the model’s classification accuracy soared to nearly 97%, including the precise identification of lung cancer subtypes—an achievement beyond the purview of ICD coding.

One of the compelling facets of this development is the model’s operational simplicity and scalability. Unlike more computationally intensive AI innovations, this approach does not demand expansive datasets or heavy resource investment. Importantly, it avoids the ethical and privacy concerns often associated with complex generative AI systems, positioning it as an immediately deployable tool for a wide range of healthcare settings, including those with limited infrastructural capacity.

The clinical implications of integrating such a model are profound. By automating the extraction of relevant diagnostic information from unstructured physician notes, the technology expedites the data availability that oncologists need for timely decision-making. This acceleration can significantly reduce the latency between diagnosis and treatment, thereby enhancing patient outcomes. Furthermore, systematically captured, high-fidelity data can underpin more robust research studies and clinical trials, fostering a cycle of continuous improvement in cancer care.

Looking forward, the MUSC team is extending this NLP framework to address other pressing clinical challenges, such as early detection of radiation necrosis—a serious, albeit rare, inflammatory side effect marked by brain swelling following radiation therapy. Identifying patients at heightened risk for such complications can enable preemptive interventions or adjustments to treatment protocols, mitigating harm and improving quality of life.

Moreover, the adaptability of the NLP model holds promise for integration with multimodal healthcare data streams. Combining unstructured clinical narratives with imaging data, laboratory results, or genomic information could yield richer, multidimensional insights into cancer biology and patient prognosis. This multidisciplinary data fusion represents the vanguard of precision oncology and offers a roadmap toward truly personalized medicine.

At its core, this research embodies a broader paradigm shift within healthcare: repurposing electronic health records from static repositories to dynamic, analyzable datasets capable of informing real-time clinical decisions. By harnessing AI-driven tools like NLP, clinicians can transcend the limitations of current documentation formats, transforming the vast expanse of textual data into actionable knowledge that benefits both patients and providers.

As cancer treatments grow increasingly sophisticated and individualized, tools that bridge the gap between raw clinical documentation and precise medical understanding will become indispensable. The MUSC Hollings Cancer Center’s NLP model demonstrates how targeted AI applications can catalyze this transformation, ensuring that technological advances translate directly into improved patient care without adding to the burdens shouldered by healthcare professionals.

Subject of Research: People

Article Title: Classifying Stereotactic Radiosurgery Patients by Primary Diagnosis Using Natural Language Processing

News Publication Date: 13-Jun-2025

Web References:
https://ascopubs.org/doi/10.1200/CCI-24-00268
https://hollingscancercenter.musc.edu/

References:
Jihad Obeid, M.D., Mario Fugal, Ph.D., et al. “Classifying Stereotactic Radiosurgery Patients by Primary Diagnosis Using Natural Language Processing.” JCO Clinical Cancer Informatics, 13 June 2025.

Image Credits:
Medical University of South Carolina / Photo by Clif Rhodes

Keywords: Cancer, Brain cancer, Artificial intelligence, Natural language processing

Anal cancer screening has historically drawn parallels with cervical cancer screening, given their shared etiological link to human papillomavirus (HPV) infections. The two primary methods of anal cancer screening—cytology, which microscopically examines cellular abnormalities, and HPV testing, designed to detect oncogenic viral strains—mirror cervical screening techniques. However, unlike cervical cancer, standardized recommendations and routine screenings for anal cancer, particularly in specific high-risk groups, have lagged behind. This new study addresses how implementing such screenings can profoundly reduce anal cancer incidence and mortality.

According to Ashish Deshmukh, Ph.D., co-leader of the Cancer Prevention and Control Research Program and first author of the study, anal cancer is eminently preventable. The computational models indicate that systematic screening could decrease anal cancer cases and mortality by as much as 65% over an individual’s lifetime. These projections highlight a significant opportunity for early intervention via screening, which could ultimately translate into saving thousands of lives and reducing disease burden substantially.

The U.S. Preventive Services Task Force (USPSTF) has yet to establish anal cancer screening guidelines due to concerns about weighing potential harms, such as anxiety and false positives, against clinical benefits and financial considerations. Deshmukh’s team sought to confront these uncertainties head-on by simulating a wide array of screening strategies, ages of initiation, and population subgroups. Their approach allows for a nuanced analysis that considers not only the efficacy but also the cost-effectiveness or “harm-to-benefit” ratio of different screening regimens.

Men who have sex with men (MSM) and who are living with HIV represented the study’s primary focus due to their markedly increased risk for anal cancer. By evaluating screening intervals and methods in this cohort, the researchers identified a particularly effective strategy centered on cytology. Their findings recommend triennial cytology screening for MSM living with HIV currently older than 35, complemented by biennial cytology for those reaching age 35 during the screening period. This hybrid approach appears to optimize the balance between maximizing cancer prevention benefits and minimizing undue psychological or physiological harms.

The researchers emphasize that screen-related anxiety and false positive rates contribute substantially to the "harms" side of the equation. Through their modeling, they examined how different screening frequencies and methodologies impact the lifetime number of false positives, which can lead to invasive follow-ups and unnecessary patient distress. The goal was to delineate strategies that curtail excessive false positives while preserving the substantive reductions in anal cancer risk brought about by early detection.

This study builds on prior guidance developed by the International Anal Neoplasia Society, where numerous screening modalities exist but without clear clinical superiority. By incorporating cost-effectiveness analyses with clinical outcomes, the study advances these guidelines towards actionable recommendations. It introduces the concept of an "efficiency frontier," a graphical tool that plots the trade-off between the number of screening procedures and the number of cancers prevented, effectively illustrating the point of diminishing returns for each strategy.

While the paper’s economic assumptions are grounded in the United States healthcare context, its broader methodological innovations have global implications. The efficiency frontier framework provides a customizable model for other countries with varying screening capacities and resource limitations. These nations could adapt the model to local epidemiological data and healthcare infrastructure, thereby facilitating the design of tailored and pragmatic anal cancer screening policies worldwide.

Another critical consideration addressed by the paper is the impact of HPV vaccination on future anal cancer risk profiles. As vaccination rates among younger populations continue to rise, the baseline risk for high-risk HPV strains, and consequently anal cancer, will likely decrease. This evolving landscape suggests that optimal screening strategies may need recalibration over time to reflect changing epidemiology, ensuring that screening remains both effective and resource-conscious.

The collaboration behind this publication was extensive, involving multiple academic medical centers, the National Cancer Institute, and the International Agency for Research on Cancer. This multidisciplinary partnership underscores the complexity and importance of rigorously evaluating cancer prevention strategies using advanced computational techniques. The integration of epidemiology, economics, clinical science, and public health modeling illustrates the future direction of precision-guided screening policies.

The study exemplifies how harnessing computational modeling can address pressing gaps in cancer prevention, where randomized clinical trial data are either unattainable due to time constraints or ethical considerations or are prohibitively expensive. By simulating potential interventions and their long-term impacts, researchers can provide policymakers with more robust evidence to craft recommendations that save lives while safeguarding limited healthcare resources.

In summary, this pivotal research lays a solid foundation for the establishment of evidence-based anal cancer screening guidelines, initially targeted at MSM living with HIV, who carry the highest disease burden. With its integration of harm-benefit analyses, cost-effectiveness assessments, and real-world applicability through the efficiency frontier concept, the study paves a clear path toward reducing anal cancer incidence and mortality. It marks a critical milestone in cancer prevention, opening new horizons for individualized and population-level health interventions globally.

Subject of Research: Screening for anal cancer among men who have sex with men living with HIV, focusing on benefits, harms, and cost-effectiveness.

Article Title: Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness Analyses

News Publication Date: 17-Jun-2025

Web References:
http://dx.doi.org/10.7326/ANNALS-24-01426

Keywords: Cancer, Cancer policy, Cancer research, Infectious diseases, Human immunodeficiency virus, Public health